Role of androgen receptor polyQ chain elongation in Kennedy's disease and use of natural osmolytes as potential therapeutic targets

IUBMB Life

Volumn 64, Issue 11, 2012, Pages 879-884

  Kumar, Raj ^a  

^a Geisinger Health Geisinger Commonwealth School of Medicine   (United States)

Author keywords

aggregation; CAG codon; neurodegenerative diseases; protein folding; spinal and bulbar muscular atrophy

Indexed keywords

ANDROGEN RECEPTOR; ORGANIC COMPOUND; OSMOLYTE; POLYGLUTAMINE; UNCLASSIFIED DRUG;

CAG REPEAT; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; HUMAN; KENNEDY DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN TARGETING; REVIEW; RNA TRANSLATION; TRANSCRIPTION REGULATION;

BIOLOGICAL AGENTS; BLOOD-BRAIN BARRIER; BULBO-SPINAL ATROPHY, X-LINKED; HUMANS; MOLECULAR CHAPERONES; OSMOSIS; PEPTIDES; RECEPTORS, ANDROGEN; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84867822718     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1088     Document Type: Review

References (48)

1. Bahar, I., Lezon, T. R., Yang, L. W., and, Eyal, E., (2010) Global dynamics of proteins: bridging between structure and function. Annu. Rev. Biophys. 39, 23-42.
2. Hardesty, B., Tsalkova, T., and, Kramer, G., (1999) Co-translational folding. Curr. Opin. Struct. Biol. 9, 111-114.
3. Kubota, H., (2009) Quality control against misfolded proteins in the cytosol: a network for cell survival. J. Biochem. 146, 609-616.
4. Naiki, H., and, Nagai, Y., (2009) Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins. J. Biochem. 146, 751-756.
5. Chiti, F., and, Dobson, C. M., (2006) Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333-366.
6. Bauer, P. O., and, Nukina, N., (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem. 110, 1737-1765.
7. Muchowski, P. J., and, Wacker, J. L., (2005) Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 6, 11-22.
8. Bates, G. P., Mangiarinim L., and, Daviesm S. W., (1998) Transgenic mice in the study of polyglutamine repeat expansion diseases. Brain Pathol. 8, 699-714.
9. Smith, D. L., Portier, R., Woodman, B., Hockly, E., Mahal, A., et al. (2001) Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiol. Dis. 8, 1017-1026.
10. Cowin, R. M., Roscic, A., Bui, N., Graham, D., Paganetti, P., et al. (2012) Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse. Behav. Brain Res. 229, 308-319.
11. Simanainen, U., Brogley, M., Gao, Y. R., Jimenez, M., Harwood, D. T., et al. (2011) Length of the human androgen receptor glutamine tract determines androgen sensitivity in vivo. Mol. Cell. Endocrinol. 342, 81-86.
12. Tang, B., Seredenina, T., Coppola, G., Kuhn, A., Geschwind, D. H., et al. (2011) Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease. Neurobiol. Dis. 42, 459-467.
13. Panet-Raymond, V., Gottlieb, B., Beitel, L. K., Schipper, H., Timiansky, M., et al. (2001) Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor. Neurotox. Res. 3, 259-275.
14. Dobson, C. M., (1999) Protein misfolding, evolution and disease. Trends Biochem. Sci. 20, 329-332.
15. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., et al. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511.
16. Dobson, C. M., and, Karplus, M., (1999) The fundamentals of protein folding: bringing together theory and experiment. Curr. Opin. Struct. Biol. 9, 92-101.
17. Burg, M. D., (1995) Molecular basis of osmotic regulation. Am. J. Physiol. 268, F983-F996.
18. Qu, Y., Bolen, C. L., and, Bolen, D. W., (1998) Osmolyte-driven contraction of a random coil protein. Proc. Natl. Acad. Sci. USA 95, 9268-9273.
19. Bauer, P. O., and, Nukina, N., (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem. 110, 1737-1765.
20. Bauer, P. O., Wong, H. K., Oyama, F., Goswami, A., Okuno, M., et al. (2009) Inhibition of rho kinases enhances the degradation of mutant huntingtin. J. Biol. Chem. 284, 13153-13164.
21. Bagatell, C. J., and, Bremner, W. J., (1996) Androgens in menâuses and abuses. N. Engl. J. Med. 334, 707-714.
22. Heinlein, C. A., and, Chang, C., (2002) Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23, 175-200.
23. Masiello, D., Chen, S. Y., Xu, Y., Verhoeven, M. C., Choi, E., et al. (2004) Recruitment of β-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol. Endocrinol. 18, 2388-2401.
24. Poletti, A., Negri-Cesi, P., and, Martini, L., (2005) Reflections on the diseases linked to mutations of the androgen receptor. Endocr. Rev. 28, 243-262.
25. Kumar, R., Atamna, H., Zakharov, M. N., Bhasin, S., Khan, S. H., et al. (2011) Role of the androgen receptor CAG repeat polymorphism in prostate cancer, and spinal and bulbar muscular atrophy. Life Sci. 88, 565-571.
26. Irvine, R. A., Ma, H., Yu, M. C., Ross, R. K., Stallcup, M. R., et al. (2000) Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum. Mol. Genet. 9, 267-274.
27. Tut, T. G., Ghadessy, F. J., Trifiro, M. A., Pinsky, L., and, Yong, E. L., (1997) Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J. Clin. Endocrinol. Metab. 82, 3777-3782.
28. Mhatre, A. N., Trifiro, M. A., Kaufman, M., Kazemi-Esfarjani, P., Figlewicz, D., et al. (1993) Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat. Genet. 5, 184-188.
29. Stanford, J. L., Just, J. J., Gibbs, M., Wicklund, K. G., Neal, C. L., et al. (1997) Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 57, 1194-1198.
30. Diamond, M. I., Robinson, M. R., and, Yamamoto, K. R., (2000) Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA 97, 657-661.
31. Palazzolo, I., Gliozzi, A., Rusmini, P., Sau, D., Crippa, V., et al. (2008) The role of the polyglutamine tract in androgen receptor. J. Steroid Biochem. Mol. Biol. 108, 245-253.
32. Nedelsky, N. B., Pennuto, M., Smith, R. B., Palazzolo, I., Moore, J., et al. (2010) Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 67, 936-952.
33. Rusmini, P., Sau, D., Crippa, V., Palazzolo, I., Simonini, F., et al. (2007) Aggregation and proteasome: the case of elongated polyglutamine aggregation in spinal and bulbar muscular atrophy. Neurobiol. Aging 28, 1099-1111.
34. Perutz, M. F., Johnson, T., Suzuki, M., and, Finch, J. T., (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 91, 5355-5358.
35. Reid, J., Betney, R., Watt, K., and, McEwan, I. J., (2003) The androgen receptor transactivation domain: the interplay between protein conformation and protein-protein interactions. Biochem. Soc. Trans. 31, 1042-1046.
36. Kumar, R., (2008) Osmolyte-induced folding of an intrinsically disordered region of glucocorticoid receptor. J. Recept. Signal Transduct. Res. 28, 465-474.
37. Závodszky, P., Kardos, J., Svingor, A., and, Petsko, G. A., (1998) Adjustment of conformational flexibility is a key event in the thermal adaptation of proteins. Proc. Natl. Acad. Sci. USA 95, 7406-7411.
38. Yancey, P. H., Clark, M. E., Hand, S. C., Bowlus, R. D., and, Somero, G. N., (1982) Living with water stress: evolution of osmolyte systems. Science 217, 1214-1222.
39. Kumar, R., and, McEwan, I. J., (2012) Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr. Rev. 33, 271-299.
40. Kumar, R., Lee, J. C., Bolen, D. W., and, Thompson, E. B., (2001) The osmolyte-induced conformation of the glucocorticoid receptor AF1/tau1 domain binds coregulators. J. Biol. Chem. 276, 18146-18152.
41. Kumar, R., Betney, R., Li, J., Thompson, E. B., and, McEwan, I. J., (2004) Induced α-helix structure in AF1 of the androgen receptorupon binding transcription factor TFIIF. Biochemistry 43, 3008-3013.
42. Soto, C., (2001) Protein misfolding and disease: protein refolding and therapy. FEBS Lett. 498, 204-207.
43. Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., and, Balch, W. E., (2009) Biological and chemical approaches to diseases of proteostasis deficiency. Ann. Rev. Biochem. 78, 959-991.
44. Tanaka, M., Machida, Y., Niu, S., Ikeda, T., Jana, N. R., et al. (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10, 148-154.
45. Nagai, Y., Fujikake, N., Ohno, K., Higashiyama, H., Popiel, H. A., et al. (2003) Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum. Mol. Genet. 12, 1253-1259.
46. Nagai, Y., Inui, T., Popiel, H. A., Fujikake, N., Hasegawa, K., et al. (2007) A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 14, 332-340.
47. Tanaka, M., Machida, Y., and, Nukina, N., (2005) A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules. J. Mol. Med. 83, 343-352.
48. McManamny, P., Chy, H. S., Finkelstein, D. I., Craythorn, R. G., Crack, P. J., et al. (2002) A mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 11, 2103-2111.